There is confusion about the NIH post, tied to a single letter ... the article "a".

From the section of the NIH paper, the following:

>> The inventors at the National Cancer Institute (NCI) a developed a non-invasive test for HLA LOH detection in liquid biopsies from blood. As a companion diagnostic (CDx), this HLA LOH detection method allows for improved patient selection. It determines patients unlikely to benefit prior to immunotherapy and thus, can avoid the toxicity, costs, and prevent delay in effective therapy. <<

Is the NCI calling out for a partner to assist in clinical research to test out a potential solution?

This LOH was a known hurdle found in the second patient dosed and maybe, just maybe, the NCI has found a solution in blood of patients. They just need financial and bench help toward POC? All the best.